DIVA Laboratories (4153) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 鈺緯

DIVA Laboratories (4153) reported revenue of NT$85.7 million for Oct 2026, +41.7% year on year and +0.0% from the previous month. Revenue for Jan–Oct 2026 was NT$802 million (+14.6% year on year).

Year-on-year revenue growth: 5 months in a row. →

In Oct 2026, it ranked No. 83 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$66.8 million24/10Nov 2024 NT$71.8 millionDec 2024 NT$84.7 millionJan 2025 NT$55.3 millionFeb 2025 NT$73.8 million25/02Mar 2025 NT$78 millionApr 2025 NT$88.2 millionMay 2025 NT$78.9 millionJun 2025 NT$67.9 million25/06Jul 2025 NT$63.8 millionAug 2025 NT$71.2 millionSep 2025 NT$62 millionOct 2025 NT$60.5 million25/10Nov 2025 NT$72.2 millionDec 2025 NT$97 millionJan 2026 NT$69.3 millionFeb 2026 NT$64.3 million26/02Mar 2026 NT$89.3 millionApr 2026 NT$74.1 millionMay 2026 NT$75.7 millionJun 2026 NT$95.2 million26/06Jul 2026 NT$83.1 millionAug 2026 NT$79.6 millionSep 2026 NT$85.7 millionOct 2026 NT$85.7 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$85.7 million+41.7%+0.0%
Sep 2026NT$85.7 million+38.2%+7.6%
Aug 2026NT$79.6 million+11.8%-4.1%
Jul 2026NT$83.1 million+30.2%-12.8%
Jun 2026NT$95.2 million+40.2%+25.8%
May 2026NT$75.7 million-4.0%+2.1%
Apr 2026NT$74.1 million-16.0%-17.0%
Mar 2026NT$89.3 million+14.6%+39.0%
Feb 2026NT$64.3 million-12.9%-7.2%
Jan 2026NT$69.3 million+25.2%-28.6%
Dec 2025NT$97 million+14.6%+34.3%
Nov 2025NT$72.2 million+0.6%+19.5%
Oct 2025NT$60.5 million-9.5%-2.5%
Sep 2025NT$62 million-4.5%-12.9%
Aug 2025NT$71.2 million+2.8%+11.7%
Jul 2025NT$63.8 million+7.3%-6.1%
Jun 2025NT$67.9 million-10.4%-13.9%
May 2025NT$78.9 million+18.0%-10.6%
Apr 2025NT$88.2 million+9.7%+13.2%
Mar 2025NT$78 million+3.0%+5.6%
Feb 2025NT$73.8 million-2.0%+33.5%
Jan 2025NT$55.3 million-22.5%-34.7%
Dec 2024NT$84.7 million+17.7%+18.0%
Nov 2024NT$71.8 million+4.4%+7.5%
Oct 2024NT$66.8 million+4.1%+2.8%

Jan–Oct 2026 cumulative: NT$802 million (+14.6% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: DIVA Laboratories vs PEC / DIVA Laboratories vs Lotus Pharm / DIVA Laboratories vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16